Published in J Proteome Res on April 14, 2007
Glycomics and disease markers. Curr Opin Chem Biol (2009) 2.04
Profile of native N-linked glycan structures from human serum using high performance liquid chromatography on a microfluidic chip and time-of-flight mass spectrometry. Proteomics (2009) 1.79
Profiling of human serum glycans associated with liver cancer and cirrhosis by IMS-MS. J Proteome Res (2008) 1.66
High-mannose glycans are elevated during breast cancer progression. Mol Cell Proteomics (2010) 1.63
Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res (2009) 1.52
The development of retrosynthetic glycan libraries to profile and classify the human serum N-linked glycome. Proteomics (2009) 1.52
Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery. Anal Chem (2010) 1.47
N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res (2012) 1.46
Carbohydrate recognition by boronolectins, small molecules, and lectins. Med Res Rev (2010) 1.44
Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics (2011) 1.36
Chemical approaches to perturb, profile, and perceive glycans. Acc Chem Res (2009) 1.33
Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J Proteome Res (2009) 1.25
Glycomic profiling of invasive and non-invasive breast cancer cells. Glycoconj J (2008) 1.24
Identifying cancer biomarkers by mass spectrometry-based glycomics. Electrophoresis (2012) 1.19
Development of a robust and high throughput method for profiling N-linked glycans derived from plasma glycoproteins by NanoLC-FTICR mass spectrometry. J Proteome Res (2009) 1.19
Glycomic analysis of sialic acid linkages in glycans derived from blood serum glycoproteins. J Proteome Res (2010) 1.13
Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J Proteome Res (2008) 1.12
N-glycosylation of colorectal cancer tissues: a liquid chromatography and mass spectrometry-based investigation. Mol Cell Proteomics (2012) 1.11
Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci U S A (2012) 1.09
Stable-isotope labeled hydrophobic hydrazide reagents for the relative quantification of N-linked glycans by electrospray ionization mass spectrometry. Anal Chem (2011) 1.07
Glycomics using mass spectrometry. Glycoconj J (2012) 1.06
Semi-automated identification of N-Glycopeptides by hydrophilic interaction chromatography, nano-reverse-phase LC-MS/MS, and glycan database search. J Proteome Res (2012) 1.04
Aberrant PSA glycosylation--a sweet predictor of prostate cancer. Nat Rev Urol (2013) 1.03
The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery. Proteomics (2012) 1.02
Enhanced sensitivity of LC-MS analysis of permethylated N-glycans through online purification. Electrophoresis (2011) 0.99
Defining putative glycan cancer biomarkers by MS. Bioanalysis (2012) 0.99
Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. Theranostics (2015) 0.96
Glycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteins. Mol Cell Proteomics (2012) 0.94
N-Glycan profiling of dried blood spots. Anal Chem (2011) 0.93
Glycomic profiling of tissue sections by LC-MS. Anal Chem (2013) 0.92
Smoking and lung cancer-induced changes in N-glycosylation of blood serum proteins. Glycobiology (2012) 0.92
Microchip electrophoresis of N-glycans on serpentine separation channels with asymmetrically tapered turns. Electrophoresis (2011) 0.92
Delineating diseases by IMS-MS profiling of serum N-linked glycans. J Proteome Res (2011) 0.92
Glycomic analysis by glycoprotein immobilization for glycan extraction and liquid chromatography on microfluidic chip. Anal Chem (2013) 0.90
Analytical glycobiology at high sensitivity: current approaches and directions. Glycoconj J (2012) 0.90
Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation. Mol Cell Proteomics (2015) 0.90
N-glycan profiling by microchip electrophoresis to differentiate disease states related to esophageal adenocarcinoma. Anal Chem (2012) 0.89
Comparative profiling of N-glycans isolated from serum samples of ovarian cancer patients and analyzed by microchip electrophoresis. J Proteome Res (2013) 0.88
Analysis of MALDI-TOF mass spectrometry data for detection of glycan biomarkers. Pac Symp Biocomput (2008) 0.87
Comparative glycomic profiling of isotopically permethylated N-glycans by liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom (2013) 0.87
Ion mobility-mass spectrometry analysis of serum N-linked glycans from esophageal adenocarcinoma phenotypes. J Proteome Res (2012) 0.87
Quantitative glycomics strategies. Mol Cell Proteomics (2013) 0.85
Capillary nano-immunoassays: advancing quantitative proteomics analysis, biomarker assessment, and molecular diagnostics. J Transl Med (2015) 0.85
Efficient Chemoenzymatic Synthesis of an N-glycan Isomer Library. Chem Sci (2015) 0.85
One-Year Plasma N-linked Glycome Intra-individual and Inter-individual Variability in the Chicken Model of Spontaneous Ovarian Adenocarcinoma. Int J Mass Spectrom (2011) 0.85
The application of SELDI-TOF-MS in clinical diagnosis of cancers. J Biomed Biotechnol (2011) 0.85
The effects of abundant plasma protein depletion on global glycan profiling using nanoLC FT-ICR mass spectrometry. Anal Bioanal Chem (2010) 0.83
Glycomic Alterations in the Highly-abundant and Lesser-abundant Blood Serum Protein Fractions for Patients Diagnosed with Hepatocellular Carcinoma. Int J Mass Spectrom (2011) 0.83
Use of activated graphitized carbon chips for liquid chromatography/mass spectrometric and tandem mass spectrometric analysis of tryptic glycopeptides. Rapid Commun Mass Spectrom (2009) 0.83
Liquid chromatography-selected reaction monitoring (LC-SRM) approach for the separation and quantitation of sialylated N-glycans linkage isomers. Anal Chem (2014) 0.82
Alteration of the serum N-glycome of mice locally exposed to high doses of ionizing radiation. Mol Cell Proteomics (2012) 0.82
CSF N-glycan profiles to investigate biomarkers in brain developmental disorders: application to leukodystrophies related to eIF2B mutations. PLoS One (2012) 0.82
Solid-phase glycan isolation for glycomics analysis. Proteomics Clin Appl (2012) 0.81
Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat. Mol Cancer (2010) 0.81
Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. EBioMedicine (2016) 0.81
Glycopeptide Site Heterogeneity and Structural Diversity Determined by Combined Lectin Affinity Chromatography/IMS/CID/MS Techniques. J Am Soc Mass Spectrom (2015) 0.79
Examination of glycan profiles from IgG-depleted human immunoglobulins facilitated by microscale affinity chromatography. Anal Chem (2012) 0.79
The serum glycome to discriminate between early-stage epithelial ovarian cancer and benign ovarian diseases. Dis Markers (2014) 0.79
Glycans and glycoproteins as specific biomarkers for cancer. Anal Bioanal Chem (2016) 0.79
Complementary Glycomic Analyses of Sera Derived from Colorectal Cancer Patients by MALDI-TOF-MS and Microchip Electrophoresis. Anal Chem (2016) 0.78
LC-MS/MS analysis of permethylated free oligosaccharides and N-glycans derived from human, bovine, and goat milk samples. Electrophoresis (2016) 0.78
Integrated peptide and glycan biomarker discovery using MALDI-TOF mass spectrometry. Conf Proc IEEE Eng Med Biol Soc (2008) 0.78
Biochemical individuality reflected in chromatographic, electrophoretic and mass-spectrometric profiles. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.77
Sub 2-μm macroporous silica particles derivatized for enhanced lectin affinity enrichment of glycoproteins. Anal Chem (2013) 0.77
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. Biomed Res Int (2015) 0.77
Recent advances in the MS analysis of glycoproteins: Capillary and microfluidic workflows. Electrophoresis (2010) 0.77
Quantitation of permethylated N-glycans through multiple-reaction monitoring (MRM) LC-MS/MS. J Am Soc Mass Spectrom (2015) 0.77
Structural Characterization of Serum N-Glycans by Methylamidation, Fluorescent Labeling, and Analysis by Microchip Electrophoresis. Anal Chem (2016) 0.77
Biological functions of fucose in mammals. Glycobiology (2017) 0.76
High-temperature LC-MS/MS of permethylated glycans derived from glycoproteins. Electrophoresis (2016) 0.76
A recombinant fungal lectin for labeling truncated glycans on human cancer cells. PLoS One (2015) 0.76
A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential. J Biomark (2014) 0.75
Software tools for glycan profiling. Methods Mol Biol (2013) 0.75
Serum N-glycome characterization and anti-carbohydrate antibody profiling in oral squamous cell carcinoma patients. PLoS One (2017) 0.75
Serum glycoprotein-derived N- and O-linked glycans as cancer biomarkers. Am J Cancer Res (2016) 0.75
Multiplexed surrogate analysis of glycotransferase activity in whole biospecimens. Anal Chem (2013) 0.75
Direct site-specific glycoform identification and quantitative comparison of glycoprotein therapeutics: imiglucerase and velaglucerase alfa. AAPS J (2014) 0.75
Probing for DNA methylation with a voltammetric DNA detector. Analyst (2014) 0.75
Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer. Oncotarget (2017) 0.75
Glycomic expression in esophageal disease. Metabolites (2012) 0.75
Is high throughput glycomics possible? Mass Spectrom (Tokyo) (2013) 0.75
Discovery of Non-invasive Glycan Biomarkers for Detection and Surveillance of Gastric Cancer. J Cancer (2017) 0.75
The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology (1982) 79.76
Measuring the accuracy of diagnostic systems. Science (1988) 27.46
Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res (1996) 3.73
Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics (2006) 3.12
Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res (2006) 2.99
Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology (2007) 2.71
Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol (2004) 2.69
Solid-phase permethylation of glycans for mass spectrometric analysis. Rapid Commun Mass Spectrom (2005) 2.27
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol (1994) 2.25
A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics (2006) 2.03
Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem (2008) 1.96
Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology (2003) 1.91
Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem (2004) 1.85
Prostate-specific antigen: current status. CA Cancer J Clin (2001) 1.63
Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology (2005) 1.60
Mass spectrometric mapping and sequencing of N-linked oligosaccharides derived from submicrogram amounts of glycoproteins. Anal Chem (1998) 1.37
Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics (2001) 1.34
Glycomic profiling of invasive and non-invasive breast cancer cells. Glycoconj J (2008) 1.24
Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma. Clin Cancer Res (2005) 1.23
Prostate-specific Antigen: Its Usefulness in Clinical Medicine. Trends Endocrinol Metab (1998) 1.20
Identification of protein-bound carbohydrates by mass spectrometry. Proteomics (2001) 1.19
High throughput quantitative glycomics and glycoform-focused proteomics of murine dermis and epidermis. Mol Cell Proteomics (2005) 1.18
A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol Chem (2003) 1.16
Fucosyltransferase activities in human pancreatic tissue: comparative study between cancer tissues and established tumoral cell lines. Glycobiology (1998) 1.07
Expression of sialyl 6-sulfo Lewis X is inversely correlated with conventional sialyl Lewis X expression in human colorectal cancer. Cancer Res (2000) 1.02
A retrospective and prospective view of glycopathology. Glycoconj J (1998) 0.98
Localization and characterization of polysialic acid-containing N-linked glycans from bovine NCAM. Glycobiology (2002) 0.97
Matrix-assisted laser desorption/ionisation mass spectrometry of oligosaccharides and glycoconjugates. J Chromatogr A (1996) 0.96
Biosynthesis of the carbohydrate antigenic determinants, Globo H, blood group H, and Lewis b: a role for prostate cancer cell alpha1,2-L-fucosyltransferase. Glycobiology (2002) 0.96
Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol (2004) 0.95
Regulation of selectin binding activity by cyclization of sialic acid moiety of carbohydrate ligands on human leukocytes. Proc Natl Acad Sci U S A (1999) 0.95
Application of proteomic strategies to the identification of urinary biomarkers for prostate cancer: a review. Biomarkers (2006) 0.93
Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope. Int J Oncol (2005) 0.92
Transfection of the nm23-H1 gene into human hepatocarcinoma cell line inhibits the expression of sialyl Lewis X, alpha1,3 fucosyltransferase VII, and metastatic potential. J Cancer Res Clin Oncol (2002) 0.90
Proteomics for the identification of new prostate cancer biomarkers. Urol Oncol (2006) 0.89
Localization of defined carbohydrate epitopes in bovine polysialylated NCAM. Biochimie (2003) 0.88
Clinical significance of ST3Gal IV expression in human renal cell carcinoma. Oncol Rep (2002) 0.88
Breast cancer progression is associated with a reduction in the diversity of sialylated and neutral oligosaccharides. Clin Chim Acta (1998) 0.87
Glycobiology. Turning sweet on cancer. Science (2003) 0.85
A proteomic approach to investigate potential biomarkers directed against membrane-associated breast cancer proteins. Electrophoresis (2006) 0.85
Targeted proteo-glycomics analysis of Sialyl Lewis X antigen expressing glycoproteins secreted by human hepatoma cell line. Anal Sci (2003) 0.84
Proteomics in prostate cancer. Curr Opin Urol (2005) 0.81
[Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)]. Gan To Kagaku Ryoho (2005) 0.80
A mechanism by which human breast carcinoma cells escape the host immune system. Neoplasma (1988) 0.80
Analysis of glycoproteins released from benign and malignant human breast: changes in size and fucosylation with malignancy. Eur J Cancer Clin Oncol (1989) 0.79
Production of milligram concentrations of free prostate specific antigen (fPSA) from LNCaP cell culture: difference between fPSA from LNCaP cell and seminal plasma. J Clin Lab Anal (1998) 0.78
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology (2007) 2.71
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
A computational approach toward label-free protein quantification using predicted peptide detectability. Bioinformatics (2006) 2.48
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol (2006) 2.35
Solid-phase permethylation of glycans for mass spectrometric analysis. Rapid Commun Mass Spectrom (2005) 2.27
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood (2007) 2.14
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol (2011) 2.10
Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem (2008) 1.96
Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol (2013) 1.81
Structural investigations of glycoconjugates at high sensitivity. Chem Rev (2002) 1.79
High-throughput solid-phase permethylation of glycans prior to mass spectrometry. Rapid Commun Mass Spectrom (2008) 1.74
Individual and gender fingerprints in human body odour. J R Soc Interface (2007) 1.65
Characterization of glycopeptides by combining collision-induced dissociation and electron-transfer dissociation mass spectrometry data. Rapid Commun Mass Spectrom (2009) 1.60
Barriers to the implementation of surveillance for stage I testicular seminoma. Int J Radiat Oncol Biol Phys (2012) 1.58
Can tumor angiogenesis be inhibited without resistance? EXS (2005) 1.55
Development of high-sensitivity ion trap ion mobility spectrometry time-of-flight techniques: a high-throughput nano-LC-IMS-TOF separation of peptides arising from a Drosophila protein extract. Anal Chem (2003) 1.54
Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res (2009) 1.52
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer (2007) 1.52
Chip-based reversed-phase liquid chromatography-mass spectrometry of permethylated N-linked glycans: a potential methodology for cancer-biomarker discovery. Anal Chem (2010) 1.47
N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J Proteome Res (2012) 1.46
Comparison of methods for profiling O-glycosylation: Human Proteome Organisation Human Disease Glycomics/Proteome Initiative multi-institutional study of IgA1. Mol Cell Proteomics (2009) 1.45
Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. AJR Am J Roentgenol (2014) 1.39
Pheromone binding by polymorphic mouse major urinary proteins. Protein Sci (2002) 1.39
Characterization of the Kallikrein-Kinin System Post Chemical Neuronal Injury: An In Vitro Biochemical and Neuroproteomics Assessment. PLoS One (2015) 1.38
Resolving and assigning N-linked glycan structural isomers from ovalbumin by IMS-MS. J Am Soc Mass Spectrom (2008) 1.37
Altered DNA polymerase iota expression in breast cancer cells leads to a reduction in DNA replication fidelity and a higher rate of mutagenesis. Cancer Res (2004) 1.33
Structural characterization of oligosaccharides using MALDI-TOF/TOF tandem mass spectrometry. Anal Chem (2003) 1.27
Comparative glycomic mapping through quantitative permethylation and stable-isotope labeling. Anal Chem (2007) 1.26
Electrophoretic analysis of N-glycans on microfluidic devices. Anal Chem (2007) 1.26
Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets. J Proteome Res (2009) 1.25
Glycomic profiling of invasive and non-invasive breast cancer cells. Glycoconj J (2008) 1.24
ProteinQuant Suite: a bundle of automated software tools for label-free quantitative proteomics. Rapid Commun Mass Spectrom (2008) 1.24
High-sensitivity analytical approaches for the structural characterization of glycoproteins. Chem Rev (2013) 1.23
Solid-phase permethylation for glycomic analysis. Methods Mol Biol (2009) 1.21
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res (2013) 1.20
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer (2005) 1.18
A proteomic survey of rat cerebral cortical synaptosomes. Proteomics (2005) 1.16
Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther (2005) 1.16
Characterizing protein glycosylation sites through higher-energy C-trap dissociation. Rapid Commun Mass Spectrom (2010) 1.16
Advancement in protein inference from shotgun proteomics using peptide detectability. Pac Symp Biocomput (2007) 1.15
Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One (2012) 1.14
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol (2007) 1.14
A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci U S A (2006) 1.13
Glycomic analysis of sialic acid linkages in glycans derived from blood serum glycoproteins. J Proteome Res (2010) 1.13
The discovery of labile methyl esters on proliferating cell nuclear antigen by MS/MS. Proteomics (2006) 1.12
Application of dissimilarity indices, principal coordinates analysis, and rank tests to peak tables in metabolomics of the gas chromatography/mass spectrometry of human sweat. Anal Chem (2007) 1.12
Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma. J Proteome Res (2008) 1.12
Automated interpretation of MS/MS spectra of oligosaccharides. Bioinformatics (2005) 1.12
Combining lectin microcolumns with high-resolution separation techniques for enrichment of glycoproteins and glycopeptides. Anal Chem (2005) 1.11
Improving confidence in detection and characterization of protein N-glycosylation sites and microheterogeneity. Rapid Commun Mass Spectrom (2011) 1.10
Identification of N-glycan serum markers associated with hepatocellular carcinoma from mass spectrometry data. J Proteome Res (2010) 1.10
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest (2004) 1.10
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs (2004) 1.09
Efficacy of glycoprotein enrichment by microscale lectin affinity chromatography. J Sep Sci (2008) 1.08
LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma. J Proteome Res (2014) 1.08
Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer (2003) 1.07
A monolithic PNGase F enzyme microreactor enabling glycan mass mapping of glycoproteins by mass spectrometry. Rapid Commun Mass Spectrom (2005) 1.06
A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res (2010) 1.06
Miniaturized separation techniques in glycomic investigations. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.06
Thermodynamic consequences of disrupting a water-mediated hydrogen bond network in a protein:pheromone complex. Protein Sci (2005) 1.06
Comparing MALDI-MS, RP-LC-MALDI-MS and RP-LC-ESI-MS glycomic profiles of permethylated N-glycans derived from model glycoproteins and human blood serum. Electrophoresis (2012) 1.06
Songbird chemosignals: volatile compounds in preen gland secretions vary among individuals, sexes, and populations. Behav Ecol (2010) 1.05
Identification of signal transduction pathways involved in constitutive NF-kappaB activation in breast cancer cells. Oncogene (2002) 1.03
Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics (2013) 1.03
Multimethodological approach to identification of glycoproteins from the proteome of Francisella tularensis, an intracellular microorganism. J Proteome Res (2010) 1.03
Seasonal variation in volatile compound profiles of preen gland secretions of the dark-eyed junco (Junco hyemalis). J Chem Ecol (2007) 1.02
New hyphenated methodologies in high-sensitivity glycoprotein analysis. J Sep Sci (2005) 1.02
High-sensitivity profiling of glycoproteins from human blood serum through multiple-lectin affinity chromatography and liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.02